Merck to Acquire Verona for $10 Billion — A Major Move into Respiratory Care, Shares of VRNA Surge 20%

Source Tradingkey

TradingKey - According to a report by the Financial Times, U.S. pharmaceutical giant Merck (MRK.US) is nearing a deal to acquire Verona Pharma (VRNA.US) for $10 billion, marking Merck’s largest biopharma acquisition since 2023.

The acquisition will expand Merck’s presence in the respiratory disease space, adding a key drug — Ohtuvayre — to its pipeline.

Ohtuvayre: A New Player in COPD Treatment

Ohtuvayre is an innovative inhaled therapy approved by the U.S. Food and Drug Administration (FDA) last year for the treatment of chronic obstructive pulmonary disease (COPD) — affecting approximately 8.6 million patients in the U.S. over the past two decades.

In Q1 2025, Ohtuvayre already achieved $71.3 million in sales, with over 25,000 prescriptions issued, exceeding market expectations.

Analysts project that Ohtuvayre could reach peak annual sales of around $4 billion by the mid-2030s.

Deal Details and Market Reaction

Sources indicated that the deal is in its final stage and may be announced as early as Wednesday. Under the proposed terms, Merck would pay $107 per American Depositary Share (ADS) — representing a 23% premium to Verona’s closing price on July 8.

Following the news, shares of Verona Pharma surged nearly 20% in after-hours trading on July 8. Year-to-date in 2025, VRNA has gained 80%, while Merck shares have fallen 18%.

As of July 9, Wall Street analysts had set an average 12-month target price of $117.92 for Verona Pharma, implying about 30% upside potential from current levels.

verona-pharma-price-forecast-analyst

Source:TradingKey

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Samsung Electronics Forecasts Stronger-Than-Expected Q3 Profit on AI Demand Samsung forecasts Q3 profit of 12.1 trillion won, boosted by strong AI chip demand.
Author  Mitrade
Oct 14, Tue
Samsung forecasts Q3 profit of 12.1 trillion won, boosted by strong AI chip demand.
placeholder
Dollar Gains as US-China Trade Tensions Ease The U.S. dollar remained steady on Tuesday following a shift in President Donald Trump’s harsh stance on tariffs against China.
Author  Mitrade
Oct 14, Tue
The U.S. dollar remained steady on Tuesday following a shift in President Donald Trump’s harsh stance on tariffs against China.
placeholder
Asian Stocks Mixed as Commodities Pause and Yen Draws AttentionAsian equity markets struggled to close the week on a weak note Friday, influenced by ongoing losses on Wall Street that extended into early Asian trading.
Author  Mitrade
Oct 10, Fri
Asian equity markets struggled to close the week on a weak note Friday, influenced by ongoing losses on Wall Street that extended into early Asian trading.
placeholder
Oil Prices Hold Steady Amid Gaza Ceasefire and US Sanctions Oil prices held steady in early Asian trading on Friday following the announcement of a ceasefire between Israel and Hamas.
Author  Mitrade
Oct 10, Fri
Oil prices held steady in early Asian trading on Friday following the announcement of a ceasefire between Israel and Hamas.
placeholder
Bitcoin drops below $110K ahead of $22B options expiry; altcoins tumbleBitcoin fell below the $110,000 mark on Friday, heading for a steep weekly loss as nearly $22 billion in cryptocurrency options were set to expire. The drop also comes as traders await key U.S. inflation data that could influence the Federal Reserve’s policy outlook.
Author  Mitrade
Sept 26, Fri
Bitcoin fell below the $110,000 mark on Friday, heading for a steep weekly loss as nearly $22 billion in cryptocurrency options were set to expire. The drop also comes as traders await key U.S. inflation data that could influence the Federal Reserve’s policy outlook.
goTop
quote